IP Library Granted Patent US 8,916,160
Granted Patent B2
US 8,916,160 · App. 13/372,870 · Granted Dec 23, 2014

Compositions and methods for the therapy and diagnosis of influenza

Inventors: Andres G. Grandea, III (Shoreline, WA); Gordon King (Shoreline, WA); Thomas C. Cox (Redmond, WA); Ole Olsen (Everett, WA); Jennifer Mitcham (Redmond, WA); Matthew Moyle (Newtown, CT); Phil Hammond (Seattle, WA)
Assignee: Theraclone Sciences, Inc.
G01N33/56983A61K2039/505C07K2317/515C07K2317/565C07K2317/76C07K2317/34C07K2317/21A61K2039/507C07K16/1018C07K2317/51G01N2333/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,160
App. No.
13/372,870
Granted
Dec 23, 2014
Kind
B2
Abstract

The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.

Claims (6)

1. A composition comprising:

(a) an isolated human monoclonal antibody, wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 771 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 778; and

(b) an isolated human monoclonal antibody, wherein said antibody comprises a VH CDR1 region comprising the amino acid sequence of NYYWS (SEQ ID NO: 72); a VH CDR2region comprising the amino acid sequence of FIYYGGNTKYNPSLKS (SEQ ID NO: 74); a VH CDR3 region comprising the amino acid sequence of ASCSGGYCILD (SEQ ID NO: 76); a VL CDR1 region comprising the amino acid sequence of RASQNIYKYLN (SEQ ID NO: 59); a VL CDR2 region comprising the amino acid sequence of AASGLQS (SEQ ID NO: 61); a VL CDR3region comprising the amino acid sequence of and QQSYSPPLT (SEQ ID NO: 63),

wherein at least one of the antibodies is directly conjugated to either a detectable label or therapeutic agent.

2. A passive immunization composition comprising the composition of claim 1 .

3. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutical carrier.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 29, 2015
From: MIDCAP FINANCIAL TRUST, AS AGENT FOR LENDERS
To: THERACLONE SCIENCES, INC.
Reel/Frame 037396/0957 →
SECURITY INTEREST Recorded Nov 19, 2015
From: THERACLONE SCIENCES, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 037146/0817 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2012
From: GRANDEA, ANDRES G., III; KING, GORDON; COX, THOMAS C.; OLSEN, OLE; MITCHAM, JENNIFER; MOYLE, MATTHEW; HAMMOND, PHIL
To: THERACLONE SCIENCES, INC.
Reel/Frame 028059/0807 →
Continuity (2)
Provisional Application 61442733 · Feb 14, 2011
Related Publication 20120207760A1 · Aug 16, 2012